Colonization is the presence of bacteria in the intestines, skin, nose, throat or anywhere in the human body without any signs of infection but with increased risk for spreading bacteria to other patients and the emergence of new infections. Screening of colonized patients is used as part of the prevention and control of multidrug-resistant (MDR) infections caused by agents such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis and multi-resistant Gram-negative bacteria. Material and methods: Data from 169 screened respondents hospitalized at the University Clinical Center Tuzla, between October 1, 2018, and May 1, 2019, were analyzed. Swabs were taken from nostrils, throat, axilla and groin area for all patients, and also from the anorectal area for 157 of them. Identification of MDR bacteria was done by phenotypical methods, according to the recommendations of EUCAST Clinical Breakpoint Table v .8.0, 2018. Results: Out of 169 patients, negative screening test results were found in 93 examinees (55.02%), and positive in 76 (44.97%). The largest number of patients undergoing screening was hospitalized in the Intensive Care Unit (Surgical Block), 73/169 (43.19%). The average screening time was 2.2 days or 53 hours. In 18/76 (23.68%) of patients with positive screening, prior to screening regular microbiological testing was done, and in the remaining 58/76 (76.3%) screening was performed first. Analyzing respondents with positive screening, 27 (35.53%) had negative findings during regular microbiological testing of different biological samples and for 49 (64.47%) different/same strains of MDR bacteria were isolated. Conclusion: Knowing the phenotypic profile of bacteria colonizing patients in intensive care units is a very useful tool in preventing their spread intra-and interhospitals.
INTRODUCTION
MDR (multidrug-resistant) bacteria are defined as bacteria with acquired resistance to at least one antibiotic from three or more antibiotic classes and are often responsible for infections associated with healthcare facilities [1] . Infections caused by MDR Gram-negative and Grampositive bacteria are difficult to treat and can cause additional problems to patients such as slow wound healing, pneumonia or sepsis. This may extend the duration of the hospital stay and in some cases, it may cause death outcome. Continuous antibiotic pressure in hospital and outof-hospital environments selects resistant bacteria such as those that represent part of normal microbial flora (colonization), as pathogenic bacteria. It has been shown that for each day of antibiotic use, the risk of infection increases by 2% in hospital and 1% in out-of-hospital facilities [2] . Colonization/infection with MDR bacteria is associated with the use of quinolones, third and fourth generations of cephalosporins and carbapenems [3] . Significant risk factors for colonization/ infection with carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae) represent the use of catheter and poor overall health status of patients with low functional status, which is also associated with the stay at long-term healthcare facilities [4] . For colonization or infection with extended-spectrum beta-lactamase (ESBL) producing bacteria, additional risk factors are the presence of gastrostomy tube, urinary catheter, nasogastric probe as well as the length of their application [5] . Colonization is the presence of bacteria in the intestines, skin, nose, throat or anywhere in the human body without any signs of infection, but with increased risk for spreading bacteria to other patients and the emergence of new infections. The spread of resistant bacterial types from patient to patient is mainly via the hands of medical personnel and from sources in the patient environment such as contaminated ventilation equipment or drinking water supply systems (faucets or water purifiers).
Prevention and control of MDR bacteria spread is based on regular hand hygiene, the use of proper personal protection, and a well maintained and clean patient environment in the hospital. Patient screening is used as part of the prevention and control of MDR infections caused by agents such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococus faecalis (VRE), and multi-resistant Gram-negative bacteria (Extended Spectrum Beta-lactamases; ESBL), cephalosporinase (AmpC -plasmid-mediated AmpC beta-lactamase) and
carbapenem-resistant bacteria (CARBA), excluding Salmonella and Shigela. It is effective in early identification of the problem of resistance spreading, efficient resolution of this problem through pathogen identification, isolation or cohorting of patients and later decolonization. Awareness of colonization is important and, therefore, the identification of those colonized with MDR strains is of critical importance for intra-and inter-hospital transfer of patients. Screening and isolation of patients with MDR bacteria result in significant cost increases in institutions where they are not practiced but these costs may be significantly reduced if applied mainly due to the reduced spread of resistant bacteria and fewer cases where antimicrobial therapy is needed [6] .
To prevent the spread of MDR bacteria, there are guidelines at the level of each country that provide advice on screening, treatment of infections and measures to prevent their spread, as well as prescribing and managing antimicrobial agents. The aim of the study was to determine the importance of screening in the emergence and spread of MDR bacteria by determining the number of patients with positive screening test results compared to the total number of screened patients, identification of the phenotype of isolated bacteria with the antibiotic profile, as well as the percentage of transmission of isolated MDR bacteria from colonization site to the emergence of infection in the same patient.
MATERIAL AND METHODS
The research was retrospective-prospective and covered the period from October 1, 2018 to May 1, 2019 Laboratory detection of ESBL-producing Enterobacterales, CARBA-producing Acinetobacter spp. and MRSA was performed by phenotypic methods. Samples taken from each examinee were cultivated on blood agar, Endo agar, and glucose broth. Following the incubation under aerobic conditions for 24 hours at 37°C, identification of an isolated strain was performed to the species level, and depending on the type of isolated bacterium, an initial screening for MDR bacteria was performed by testing antimicrobial susceptibility by disk diffusion and microdilution methods (using VITEK 2 Compact, automated instrument, bioMėrieux, France), in accordance with institution's official procedures. The suspected presence of ESBL producers was based on the existence of synergism between the thirdgeneration cephalosporins and amoxicillin/clavulanic acid disks as well as the inhibition zone diameter value for ceftazidime (10 μg) <22 mm, ceftriaxone (5 μg) <23, cefotaxime (5 μg) <21 mm and cefpodoxime (10 μg) <21 mm. In addition to the disk diffusion method, ESBL isolate detection was done by Vitek 2 Compact instrument, which identifies the phenotype and determines the minimum inhibitory concentration (MIC). Identification of ESBL producers was confirmed when MIC for above-mentioned antibiotics was as follows: cefotaxime/ceftriaxone and ceftazidime MIC>1 mg/L as well as for cefpodoxime MIC>1 mg/L. Each positive isolate was also cultured on chromogenic media for ESBL screening (bioMėrieux, France). The growth of dark red to reddish colonies verified the identification of ESBL-producing Escherichia coli (E. coli), and metallic blue colonies ESBL-producing Klebsiella, Citrobacter and Enterobacter.
Using the same test we also determined the presence/ absence of AmpC producers. When the diameter for ceftazidime, cefotaxime, ceftriaxone was within the zone of resistance, there was no synergism with clavulanic acid, and the isolate resistant to cefoxitin with a zone of inhibition of ≤ 19 mm was considered a AmpC β lactamase producer.
Screening test for the detection of carbapenemaseproducing Enterobacterales (CPE) was performed by disk diffusion method using meropenem disk (10 μg). Carbapenemase-producer testing was considered justified if the inhibition zone diameter for meropenem was <25 mm. Screening cut-off for the presence of carbapenemase-producing Enterobacterales was considered positive if the inhibition zone for meropenem was <28 mm [7] .
Detection of carbapenemase-producing Acinetobacter spp. and Pseudomonas aeruginosa (P. aeruginosa) was performed by disk diffusion susceptibility testing to meropenem (10 μg) and, after obtaining positive results (resistance to meropenem), by phenotypic resistance type identification by VITEK 2 Compact (card AST-N232) and MIC determination for meropenem. If the inhibition zone diameter values for Acinetobacter spp.) were below 15 mm by disk diffusion method or MIC above 8 mg/L, and for P. aeruginosa below 18 mm or MIC over 8 mg/L, we considered that the isolate was a carbapenemase-producer. Each positive isolate tested for carbapenemase-resistance was transferred to a chromogenic carbapenemase CHROMID CARBA resistance detection medium (bioMėrieux, France). In agreement with the manufacturer's guidelines, only blue colonies were considered to be suspected Enterobacterales and white (i.e., colorless) colonies were considered to be Acinetobacter [8] .
The first indication of MRSA presence was the resistant result to cefoxitin (30 μg), by disk diffusion and microdilution methods. S. aureus with inhibition zone for cefoxitin of <22 mm and MIC> 4 mg/L was reported as methicillin-resistant. After confirming the presence of MRSA, the same isolate was transferred to a chromogenic CHROMID MRSA agar (bioMėrieux, France). Seeded plates were incubated for 24 hours at 35°C. MRSA positive strains were reported if single green colonies were detected, while no growth observed was considered MRSA negative sample. MRSA strain phenotype verification was performed by automated procedure on VITEK 2 Compact, using AST-P580 and AST-P586 susceptibility cards.
For each isolate a complete antibiogram was done using Kirby-Bauer disk diffusion test and values recorded according to the recommendations of EUCAST Clinical Breakpoint Tables v. 8.0, valid from 2018-01-01. For Enterobacterales susceptibility to ampicillin (10 μg), amoxicillin/clavulanate (30 μg), ceftazidime (10 μg), cefuroxime (30 μg), cefotaxime (5 μg), cefepime (30 μg), amikacin (30 μg), gentamicin (10 μg), tobramycin (10 μg), trimethoprim/ sulfamethoxazole (25μg), ciprofloxacin (5 μg), levofloxacin (5 μg), imipenem (10 μg), meropenem (10 μg), colistin (10 μg), ampicillin/sulbactam (10/10 μg ) and rifampicin (5 μg) was examined. For Acinetobacter susceptibility to imipenem (10 μg), meropenem (10 μg), ciprofloxacin (5 μg), levofloxacin (5 μg), amikacin (30 μg), gentamicin (10 μg), tobramycin (10 μg), trimethoprim/sulfamethoxazole (25 µg), colistin (10 µg), ampicillin/sulbactam (10/10 µg) and rifampicin (5 µg) was investigated [7, 9] . According to the EUCAST recommendations, colistin sensitivity was determined by MIC breakpoints (mg/L). Because of the high cost of the E test, in our lab colistin sensitivity for CARBAproducing Acinetobacter and Klebsiella pneumoniae was determined based on MIC breakpoints using VITEK 2 Compact system, after the disk diffusion method. Acinetobacter spp. was considered colistin sensitive by disk diffusion method if the inhibition zone was ≥14 mm, while K. pneumoniae and Enterobacter spp. were considered sensitive for colistin if the inhibition zone was ≥14 mm, and resistant if it was ≤11 mm. [10, 11] . For all samples for which the inhibition zone was ≤14 mm, MIC was verified by VITEK 2 Compact system.
Statistical analysis
For statistical data processing we used the methods of standard descriptive statistics: Student t-test and Chi square test. The value of p <0.05 was considered statistically significant. The data were processed in the statistical program IBM SPSS 20.0.
RESULTS
Out of a total of 169 patients, negative screening test results were obtained for 93 (55.02%) and positive for 76 (44.97%) examinees. The largest number of patients undergoing screening was hospitalized at the Intensive Care Unit -Surgical Block 73/169 (43.19%), followed by the Department of Hepato-Pancreato-Biliary Surgery 44/169 (26.03%) and the smallest number at the Department of Children's Orthopedics, the Intensive Care Unit -Blue Building, and the Department of Aloplastics and Sport Trauma, 2/169 (1.18%) for each ( Figure 1 ). The average time of completion of screening was 2.2 days or 53 hours. For 17/93 (18.27%) of patients with negative screening results, regular microbiological testing was conducted before screening, mainly serological analysis of influenza and hepatitis, and tests for tuberculosis, while for 76/93 (81.72%) screening was done first. In 18/76 (23.68%) of patients with positive screening, prior to screening, microbiological testing was performed and for the remaining 58/76 (76.3%) screening was done first. A student's t test showed a statistically significant difference (P = 0.0316; t = 5.4915; df = 2) between the group of subjects with positive and negative screening versus the time of screening completion.
Intensive

Negative screening
After obtaining negative screening results, from wound swabs, aspirates, surgical drain contents and hemocultures of 13/93 (13.9%) of patients MDR bacteria were isolated. There were 8 ESBL-producing K. pneumoniae, 2 ESBL-producing E. coli and 7 CARBAproducing Acinetobacter isolated. The patients were hospitalized at the Intensive Care Unit -Surgical Block (8/13), Hepato-Pancreato-Biliary Surgery (2/13), Colorectal Surgery (2/13) and Children's Orthopedics (1/13).
After negative screening results, one patient had ESBLproducing K. pneumoniae isolated from the surgical drain content swab, and in the second screening, of the same patient, the same strain of K. pneumoniae was isolated from the inguinal swab. All isolated strains of ESBL-producing K. pneumoniae were susceptible to amikacin, imipenem and meropenem, and resistant to ampicillin, amoxicillin/clavulanate, cefazoline, cefuroxime, cefotaxime, cefepime, tobramycin, trimethoprim/sulfamethoxazole, ciprofloxacin, and levofloxacin (Table 2) . CARBA-producing Acinetobacter was in all isolates susceptible to colistin and had a variable susceptibility to tobramycin and ampicillin/sulbactam. ESBL-producing E. coli strains were all sensitive to amikacin, trimethoprim/ sulfamethoxazole, imipenem, and meropenem.
Positive screening
Analysis of one isolate from each examinee (some had more than one positive, with one or two different types of isolated bacteria), showed that ESBL-producing K. pneumoniae was isolated from 23/76 (30.26%) of patients, CARBA-producing K. pneumoniae 13 The same strain of ESBL-producing K. pneumoniae was isolated from axilla and inguinal regions for 3/12 (41.66%) of patients, and also from sputum, abdominal and thoracic drain contents.
After obtaining positive screening results by isolating CARBA-producing K. pneumoniae from axilla regions and throat swabs for 2/12 (16.66%) of patients, subsequently from wound swabs, besides the same strain of Klebsiella, ESBL-producing K. pneumoniae was isolated.
One patient (1/12; 8.33%) had, after the positive screening results of groin area (CARBA-producing K. pneumoniae), the same strain of Klebsiella isolated from the wound swab and surgical drain content.
For 12/30 patients who in screening (positive screening and isolation of the same strain(s) of MDR bacteria) had CARBA-producing Acinetobacter spp., screening was performed first for 6 of them.
For 8/12 (66.66%) of patients who had CARBAproducing Acinetobacter spp. isolated during screening, the same strain was isolated from the wound swabs, surgical drain contents, sputum, aspirate and urine cultures.
For 4/12 (33.33%) of patients with CARBA-producing Acinetobacter spp. and ESBL-producing K. pneumoniae, isolated by screening from axilla and groin swabs, the same strain of Acinetobacter was isolated from wound swabs and urine cultures. Of the remaining six patients (6/12, 20%), from three ESBL-producing P. mirabilis was isolated, from two ESBL-producing Enterobacter spp. and CARBAproducing Enterobacter spp., and from one AmpCproducing E. coli.
For two patients who in screening and biological samples had ESBL-producing P. mirabilis present, in biological samples also had CARBA-producing Acinetobacter spp.
Types of isolated MDR bacteria from different biological samples of patients with positive screening results
Analyzing the microbiological results obtained from samples of wound swabs, surgical drain contents, aspirates, hemocultures, urine cultures and other biological samples of patients with positive screening, 101 following pathogens were isolated: 38 (37.62%), CARBA-producing Acinetobacter spp.; 9 (8.91%), CARBA-producing K. pneumoniae; 2 (1.98%), CARBA-producing Enterobacter spp.; 24 (23.76%), ESBL-producing K. pneumoniae; 12 (11.88%), ESBLproducing P. mirabilis; 8 (7.92%), ESBL-producing E coli; 7 (6.93%), ESBL-producing Enterobacter spp.; and one isolate (0.99%) of ESBL-producing Morganellae morganii.
Antimicrobial susceptibility of MDR isolates from screening
All isolates of CARBA-producing Acinetobacter spp., K. pneumoniae and Enterobacter spp. were susceptible to colistin, and varying resistance to amikacin was recorded for Acinetobacter spp. (85.29%), K. pneumoniae (55.55%) and Enterobacter spp. (25%). Resistance to tobramycin was 52.94% for CARBA-producing Acinetobacter spp. and 50% for CARBA-producing Enterobacter spp. Resistance to trimethoprim/sulfamethoxazole was detected for 91.17% of CARBA-producing Acinetobacter spp. and 66.66% CARBA-producing K pneumoniae. 38.88% of CARBA-producing K. pneumoniae isolates had an intermediate sensitivity/resistance to imipenem. Resistance to ampicillin/sulbactam was detected in 94.11% of CARBA-producing Acinetobacter spp. and 25% CARBA-producing Enterobacter spp. To all other antibiotics shown in Table 2 , CARBA-producing isolates of above-mentioned bacteria were resistant. Table 2 , the ESBL-producing isolates of K. pneumoniae, E. coli, Enterobacter spp., and P. mirabilis were resistant.
MRSA isolates were resistant to penicillin and cefoxitin and sensitive to amikacin, gentamicin, rifampicin, trimethoprim/sulfamethoxazole, vancomycin, clindamycin, erythromycin, ciprofloxacin and fusidic acid.
Antimicrobial susceptibility of MDR isolates from biological samples of patients with positive screening
The difference in resistance of MDR isolates from biological samples of patients with positive screening results was found for amoxicillin/clavulanate, amikacin, tobramycin, imipenem and ampicillin/ sulbactam (Table 3) . 
DISCUSSION
MDRs are often found in the intestines, skin and mucous membranes where they do not cause damage, but can cause infections at other sites in the human body, mostly in immunocompromised patients due to other primary illnesses, injuries or previous hospitalizations. Early detection of patients colonized or infected with MDR Gram-negative and Gram-positive bacteria is important for effective management of their status and for timely interventions to prevent the subsequent spread of resistant bacteria. Screening is divided into conventional, where detection of resistant bacterial types is achieved by phenotypic methods, and rapid screening, based on molecular detection of genes that encode resistance to multiple antibiotics.
The significance of screening was examined in a multicentric study [12] in which an assessment has been made of the incidence of gastrointestinal colonization with ESBL-producing Enterobacterales in patients with malignancies and risk of subsequent bloodstream infections. Analyzing data from ten different studies, an overall prevalence of colonization was found to be 19% and examining the geographical regions, 15% was in Europe and 31% in Asia. It has also been found in this study that patients with malignancies colonized with ESBL-producing Enterobacterales are by 12.98 times more likely to develop sepsis than uncolonized. For this reason, screening measures need to be evaluated to determine their clinical benefit. Active screening represents an overview of asymptomatic patients to detect colonization with the investigated pathogen(s) and may be of utmost importance in determining colonization with MDR bacteria. According to the recommendations of the "Joint Working Group", University College London Hospitals, UK, active screening is advised and not passive surveillance of high risk cases, which include patients with isolated CARBA-producing Gramnegative bacteria from rectal and wound swabs, hospitalized at the Intensive Care Units (ICUs) or referred to by adult care institutions (e.g. nursing homes).
Screening for MDR Enterobacterales and P. aeruginosa should be performed using rectal swabs (with visible material) or stool samples (and urine sample if a catheter is present). For screening of Acinetobacter, samples of skin swabs should be taken or urine, if a catheter is used or respiratory mucus if endotracheal tube is used. Patients who have not been identified as resistant bacteria carriers should be re-screened weekly even after leaving affected hospital units until new cases with negative screening results are identified for more than seven days after the discharge of a resistant bacteria carrier. After obtaining positive screening test results, it is necessary to take precautionary measures and place infected and colonized patients in single rooms if available or cohort patients in the following order of priority: CARBA-producing Enterobacterales, CARBA-producing Acinetobacter baumannii (A. baumannii), ESBL-producing Klebsiella spp., CARBAproducing P. aeruginosa, ESBL-producing E. coli and other Enterobacterales, and AmpC-producing Enterobacterales [13] .
In addition to the above-mentioned measures, contact precautions are very important because, despite the application of such recommendations, a steady increase in ESBL-producing E. coli and K. pneumoniae has been recorded globally. This trend is of particular concern, because the ESBL-producing Enterobacterales exhibit a reduced response rate to antimicrobial treatment, resulting in increased use of carbapenems, which promotes the formation of bacteria resistant to the same. It is considered that the transmission rate is at least two times higher in patients colonized with ESBL-producing K. pneumoniae than those colonized with ESBL-producing E. coli. Among patients sharing a common room in intensive care units, the likelihood they will be colonized or infected with ESBL-producing E. coli if only one patient is already colonized is 2.6% while in hospital for geriatric rehabilitation it is 8.6%, with an increase in transmission with the duration of room sharing [14] .
In our study of 76 patients with positive screening test results, from 23 of them, ESBL-producing K. pneumoniae was isolated and from 9 the same strain was isolated from different biological material (when regular microbiological testing was conducted). From 6 patients with positive screening and isolated ESBLproducing E. coli, only for one examinee, the same strain was also isolated from various biological samples. From the results, it could be seen that in our study the percentage of K. pneumoniae (ESBL) transmission from colonization to isolation in biological samples (39.13%) was higher than E. coli (ESBL; 16.66%). Of 23 patients, for 6 of them, ESBL-producing K. pneumoniae was isolated from several types of screened material, while ESBL-producing E. coli was found in only one sample. Using universal screening by examining swabs taken from throat, axilla and groin area from patients being admitted to intensive care unit in Cairo (Egypt), Fouda et al. [15] showed colonization with ESBL-producing Enterobacterales (33%), MDR Gram-negative bacteria (13%) and MRSA (63%), and higher mortality of MDR colonized patients in intensive care units. Colonization with ESBL-producing Enterobacterales in our study was found in 26.03% (44/169) of patients, 18.34% (31/169) with CARBA-producing Acinetobacter spp., 10.05% (17/169) with CARBA-producing K. pneumoniae and Enterobacter spp., and 0.59% (1/169) with MRSA.
Huskins et al investigating the importance of screening of patients at the admission to intensive care units did not find the reduced prevalence of MRSA and VRE despite the precautionary measures of prevention undertaken for colonized patients [16] . However, according to reports from the United States Agency for Research and Quality in Healthcare, it was established that the application of universal screening of MRSA carriers at the admission to intensive care units significantly reduces the risk of MRSA infections [17] .
Discordance in the assessment of the significance of screening according to numerous authors is related to the non-uniformed reporting method of isolation and identification of MDR bacteria from throat swabs, axilla, groin and anorectal areas, as well as to following the recommendations of conducting screening for all high-risk patients at the moment of admission to intensive care units. It is recommended that the screening test should be completed for less than 48 hours, and after 24 hours preliminary results using fast phenotypic methods should be reported [18] . In our research, the average screening time was 53 hours (2.2 days). The reason for this slight deviation from recommendations is the dynamics of the process of receiving the material and issuing the results. We also found that there was a statistically significant difference (p = 0.0316) between the group of patients with positive and negative screening test results in terms of the time of sampling the material for screening (screening of patients before/after entering the intensive care unit). This certainly indicates the importance of timely screening in preventing the spread of resistant bacteria. A certain number of our patients had regular microbiological testing done prior to screening, and an explanation for this is that the patients in our study were hospitalized in different departments at the UCC Tuzla, not just the Intensive Care Unit.
The phenotypic profile of MDR antibiotic bacteria is constantly changing. The global spread of CARBAproducing K pneumoniae, and the use of colistin as a therapeutic option has led to the development of resistance to this antibiotic in many countries in Europe (Italy, Greece, Hungary, Turkey), as well as the United States. Analyzing data from 21 hospitals on resistance of CARBA-producing K. pneumoniae isolates, Moneco et al [19] found that 43% of isolates were resistant to colistin, 16% to gentamicin, 82% to trimethoprim/sulfamethoxazole, 6% to tigecycline and 1% to all four antibiotics. In our study, we did not find resistance to colistin, while all isolates of CARBAproducing K. pneumoniae and Enterobacter spp. were resistant to gentamicin. Resistance to trimethoprim/ sulfamethoxazole was found in 55.55% of CARBAproducing K. pneumoniae isolates.
Increased resistance of A. baumannii isolates from clinical sample were recorded throughout Europe. Maraki et al [20] found a significant increase in A. baumannii resistance during the period from 2010 to 2014 to imipenem (72% to 88.9%), meropenem (37.9% to 89.4%), gentamicin (41.7% to 84.2%), tobramycin (59.3% to 77.8%), tetracycline (67.8% to 90.5%), tigecycline (2.9% to 41.3%), and colistin (0% to 7.9%). Significant reductions in resistance were found to amikacin (76.8% to 42.9%) and trimethoprim/ sulfamethoxazole (91.5% to 59.3%). The most common A. baumannii phenotype, reported in this study, was resistance to ampicillin/sulbactam, cephalosporins, carbapenems, aminoglycosides, ciprofloxacin, and tigecycline.
CARBA-producing Acinetobacter isolated in our study by screening were resistant to all tested antibiotics (100%), except for amikacin (85.29%), tobramycin (52.94%), trimethoprim/sulfamethoxazole (91.17%), ampicillin/sulbactam (94.11%). Isolates from clinical specimens of the same patients, obtained during the regular microbiological testing, showed higher resistance to tobramycin (71.05%) and trimethoprim/ sulfamethoxazole (94.73%) and lower to ampicillin/ sulbactam (73.64%).
CONCLUSION
Awareness of the need for active screening of colonized patients to prevent the spread of multi-resistant bacteria is essential for patients as well as for the management of health care institutions. Analyzing our data we found that it is very important to follow the rule of active screening of patients before entering the intensive care unit. Colonization of patients is often caused by two or even three different types of MDR bacteria and the highest percentage of transmission of these bacteria from the place/site of screening to other body sites of the same patient where the infection was found, is for ESBL-producing K. pneumoniae and CARBA-producing Acinetobacter spp. Greater resistance was found for MDR bacteria isolated from different biological samples (during regular microbiological testing) than those detected during screening.
